Date: July 1, 2024
HeXun Biosciences (6986), a company listed on the Emerging Stock Market, has recently reached a new milestone in its operations. HeXun has signed a "Mesenchymal Stem Cell Drug - Production Technology" licensing agreement with JY BioMedical. HeXun will provide JY BioMedical with its umbilical cord-derived mesenchymal stem cell (UC-MSC) culture technology and exosome production technology. The two parties will collaborate on the development of exosomes derived from umbilical cord-derived MSCs, which JY BioMedical will use in the development of various products, including medical devices, new drugs, and skincare products. These products can be applied in wound healing treatments and aesthetic medicine.
In the first phase, HeXun will receive a signing fee of USD 1.8 million, followed by additional licensing fees amounting to USD 4.2 million, based on phased conditions and development progress. The total contract value could reach USD 6 million. This marks HeXun's first technology licensing agreement, demonstrating that not only has its CDMO/CMO business matured, but also that its exosome technology has reached a stage where it can be licensed. With the growing market demand for exosomes, HeXun's operations are expected to continue experiencing strong growth momentum.
JY BioMedical is a professional pharmaceutical and biotech company that initially focused on the development of functional health products, aiming to create supplements specifically for chronic diseases. During the COVID-19 pandemic, the company transitioned into biotech and pharmaceutical R&D. In 2020, it collaborated with a medical center on the academic-industry development and validation of the DC-PDL1 cancer vaccine, while also partnering with top international research institutions.
Since 2022, JY BioMedical has recognized the potential of exosomes and has continually commissioned HeXun to develop and research exosome production processes. The goal is to use exosomes as raw materials to develop various medical devices and pharmaceuticals, with a primary focus on wound healing and aesthetic applications. After the licensing agreement, HeXun will continue to handle production, while JY BioMedical will invest resources in the development of medical devices, new drugs, and international market collaborations.
Comments